AstraZeneca said Thursday that preliminary data from a trial it conducted with its COVID-19 injection, Vaxzevria, showed that it generated a higher antibody response against its Omicron variant and others, including Beta, Delta, Alpha and Gamma, when it was used. given as a third booster dose.
The increased response was seen in people previously vaccinated with Vaxzevria or an mRNA vaccine, the drugmaker said, adding it would provide this data to regulators around the world given the urgent need for boosters.
AstraZeneca developed the vaccine with researchers at the University of Oxford, and last month lab research showed that a three-dose course of Vaxzevria was effective against the rapidly spreading new variant.
The data is the first the company has released from its trials of boosters to its vaccine.
The company said it adds to the growing evidence supporting a third dose of its vaccine regardless of primary vaccination schedule.
“These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, greatly boosts immunity against COVID-19,” Andrew Pollard, head of the Oxford Vaccine Group, said in a statement. .
A large UK study in December found that the injection of AstraZeneca increased antibodies when given as a booster after the first vaccination with its own injection or that of Pfizer, which is based on mRNA technology.
However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the greatest boost to antibodies when given as a booster dose.
(Except for the headline, this story has not been edited by DailyExpertNews staff and has been published from a syndicated feed.)